HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics, Inc. - Common Stock -6.34% Pre
Tempest Therapeutics, Inc. - Common Stock TPST | 3.25 3.27 | -6.34% +0.62% Pre |
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:
TPST) with a Buy and maintains $47 price target.